Sugi Predict

Sugi Predict / Compounds / SCHEMBL1663438

SCHEMBL1663438

SCHEMBL1663438

O=[N+]([O-])c1ccc(OCc2ccccc2)cc1[N+](=O)[O-]

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.57
▸ KMT2A Q03164 4/20 0.57
▸ NPC1 O15118 1/20 0.57
▸ RAB9A P51151 1/20 0.57
▸ ATM Q13315 1/20 0.57
▸ BACE1 P56817 1/20 0.55
▸ AR P10275 1/20 0.53
▸ ALOX5 P09917 1/20 0.53
▸ TLR4 O00206 1/20 0.52
▸ TLR2 O60603 1/20 0.52
▸ MAOA P21397 1/20 0.52
▸ MAOB P27338 1/20 0.52
▸ CTSV O60911 2/20 0.52
▸ CTSL P07711 2/20 0.52
▸ PTGES O14684 1/20 0.51
▸ MAPT P10636 2/20 0.50
▸ PIN1 Q13526 2/20 0.49
▸ TOP1 P11387 1/20 0.49
▸ PKM P14618 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30832846 1.00 MEN1 (0.57) MEN1KMT2ANPC1RAB9AATM
SCHEMBL29502844 0.88 POLB (0.58) MEN1KMT2ANPC1RAB9AATM
SCHEMBL3235424 0.88 BACE1 (0.59) MEN1KMT2ANPC1RAB9AATM
SCHEMBL7907625 0.88 MEN1 (0.54) MEN1KMT2ANPC1RAB9AATM
SCHEMBL5421861 0.88 POLB (0.58) MEN1KMT2ANPC1RAB9AATM
SCHEMBL1708317 0.86 MAPT (0.64) MEN1KMT2ANPC1RAB9AATM
SCHEMBL519418 0.86 PTGES (0.61) MEN1KMT2ANPC1RAB9AATM
SCHEMBL8699359 0.86 MEN1 (0.53) MEN1KMT2ANPC1RAB9AATM
SCHEMBL29502955 0.86 MAPT (0.56) MEN1KMT2ANPC1RAB9AATM
SCHEMBL1061802 0.86 MAPT (0.56) MEN1KMT2ANPC1RAB9AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12365681-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2025-07-22 — — US disclosed
CN-118206529-A Dihydrobenzimidazolone C4医药公司 2024-06-18 — — CN disclosed
US-20240109889-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2024-04-04 — — US disclosed
CN-111315735-B Dihydrobenzimidazolone C4医药公司 2024-03-08 — — CN disclosed
US-11787802-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2023-10-17 — — US disclosed
US-20220289738-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2022-09-15 — — US disclosed
US-11254672-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2022-02-22 — — US disclosed
EP-3679027-A1 DIHYDROBENZIMIDAZOLONES C4 Therapeutics, Inc. (US) 2020-07-15 — — EP disclosed
US-20200207764-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2020-07-02 — — US disclosed
CN-111315735-A Dihydrobenzimidazolones C4医药公司 2020-06-19 — — CN disclosed
US-6897208-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2005-05-24 — — US disclosed
EP-1441725-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS Aventis Pharmaceuticals Inc. (US) 2004-08-04 — — EP disclosed
CN-1159303-C Preparation of intermediate for monocyclic beta-lactams derivatives ER 2004-07-28 — — CN disclosed
US-20040048868-A1 Benzimidazoles AVENTISUB LLC 2004-03-11 — — US disclosed
WO-2003035065-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS AVENTIS PHARMACEUTICALS INC (US) 2003-05-01 — — WO disclosed
CN-1067053-C A process for preparing the intermediate of the derivatives of monocycle beta-lactam antibiotics SQUIBB & SONS INC (US) 2001-06-13 — — CN disclosed
CN-1251836-A Preparation of intermediate for monocyclic beta-lactams derivatives SQUIBB & SONS INC (US) 2000-05-03 — — CN disclosed
CN-1031825-C Process for the preparation of heteroaroyl derivatives of monocyclic beta-lactam antibiotics SQUIBB & SONS INC (US) 1996-05-22 — — CN disclosed
CN-1113228-A A process for preparing the intermediate of the derivatives of monocycle beta-lactam antibiotics SQUIBB & SONS INC (US) 1995-12-13 — — CN disclosed
CN-1061414-A HETEROAROYL DERIVATIVES OF MONOCYCLIC BETA-LACTAM ANTIBIOTICS SQUIBB & SONS INC (US) 1992-05-27 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200207764-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT CRBN, CUL4A, ADRM1 MEN1 2663/4885KMT2A 1817/4885NPC1 3010/4885
US-20040048868-A1 Benzimidazoles CDK9, BMX, CDKN1A MEN1 1460/4885KMT2A 1844/4885NPC1 2551/4885
US-12365681-B2 Dihydrobenzimidazolones for medical treatment CRBN, CUL4A, ADRM1 MEN1 2663/4885KMT2A 1817/4885NPC1 3010/4885
US-20240109889-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT CRBN, CUL4A, ADRM1 MEN1 2663/4885KMT2A 1817/4885NPC1 3010/4885
US-20220289738-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT CRBN, CUL4A, ADRM1 MEN1 2663/4885KMT2A 1817/4885NPC1 3010/4885
US-11787802-B2 Dihydrobenzimidazolones for medical treatment CRBN, CUL4A, ADRM1 MEN1 2663/4885KMT2A 1817/4885NPC1 3010/4885
US-11254672-B2 Dihydrobenzimidazolones for medical treatment CRBN, CUL4A, ADRM1 MEN1 2663/4885KMT2A 1817/4885NPC1 3010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.